Dr. Ram Yogendra

so in 2021 we by the end of the end of 2021 we had actually found an immune signature in post-covid vaccine syndrome we also found the spike protein from the vaccine in the monocytes in the vascular monocytes of these patients we knew it was the spike protein because we sequenced them so it wasn't just using flow cytometry but we sequenced them and all of this information

so in 2021 we by the end of the end of 2021 we had actually found an immune signature in post-covid vaccine syndrome we also found the spike protein from the vaccine in the monocytes in the vascular monocytes of these patients we knew it was the spike protein because we sequenced them so it wasn't just using flow cytometry but we sequenced them and all of this information

was on our paper and it's been in the preprint service since 2021 so none of this is new when people say the Yale study was was new it's like no we knew this in 2021 internally in our group we had doctors in our team who told me Rob don't we should not be studying this we should not be looking at this in our own group my God do not put my name on this paper

was on our paper and it's been in the preprint service since 2021 so none of this is new when people say the Yale study was was new it's like no we knew this in 2021 internally in our group we had doctors in our team who told me Rob don't we should not be studying this we should not be looking at this in our own group my God do not put my name on this paper

And, you know, we have an ethical and moral duty. I'm not making this up. This is not data or something I'm making up. It's just we find something we have to present it to not only the scientific community, but the public, and then let the decision makers decide what they're going to do with that information.

And, you know, we have an ethical and moral duty. I'm not making this up. This is not data or something I'm making up. It's just we find something we have to present it to not only the scientific community, but the public, and then let the decision makers decide what they're going to do with that information.

And so that's when we delayed the paper, you know, even submitting it till about the middle of 2020 to the journal. We wanted to get the FDA, the NIH and the CDC engaged.

And so that's when we delayed the paper, you know, even submitting it till about the middle of 2020 to the journal. We wanted to get the FDA, the NIH and the CDC engaged.

now in 2021 april of 2021 we were introduced by congressman mike doyle of pittsburgh to francis collins at the nih and there's this is a public meeting it's on april 29th of 2021 when he was first introduced to all of our research and we sent all of this to dr collins And Congressman Doyle specifically told Dr. Collins to any correspondence with us that he wanted to be CC'd on this.

now in 2021 april of 2021 we were introduced by congressman mike doyle of pittsburgh to francis collins at the nih and there's this is a public meeting it's on april 29th of 2021 when he was first introduced to all of our research and we sent all of this to dr collins And Congressman Doyle specifically told Dr. Collins to any correspondence with us that he wanted to be CC'd on this.

Well, crickets. We sent all our papers to Dr. Collins. We were on a call with them and he said, oh, this is very interesting. We sent our all our data to the FDA, to Dr. Woodcock, to Dr. Marks, all of our data, what we found. And we were not trying to cause controversy or we say, hey, look, we found something.

Well, crickets. We sent all our papers to Dr. Collins. We were on a call with them and he said, oh, this is very interesting. We sent our all our data to the FDA, to Dr. Woodcock, to Dr. Marks, all of our data, what we found. And we were not trying to cause controversy or we say, hey, look, we found something.

We're finding the spike protein in potentially these in these vaccines weeks and months after after vaccination.

We're finding the spike protein in potentially these in these vaccines weeks and months after after vaccination.

Sure. So we submitted it to six different journals and going through the peer review process. And the first journal said, this is a low priority paper, low priority topic. And that's on my Twitter feed. I posted all of the receipts on there. So anyone that wants to take a look and go see it. One of the other journals said, this is preliminary information.

Sure. So we submitted it to six different journals and going through the peer review process. And the first journal said, this is a low priority paper, low priority topic. And that's on my Twitter feed. I posted all of the receipts on there. So anyone that wants to take a look and go see it. One of the other journals said, this is preliminary information.

Finally, one journal said, we will accept for peer review. They came back to me and they said, well, this is all copied from another paper. And I said, well, this is from our paper where we found the spike protein in the long COVID patients. It's the same materials and methods section. And the same journal that had published it, now when it came to the vaccine,

Finally, one journal said, we will accept for peer review. They came back to me and they said, well, this is all copied from another paper. And I said, well, this is from our paper where we found the spike protein in the long COVID patients. It's the same materials and methods section. And the same journal that had published it, now when it came to the vaccine,

they had questions about the materials and methods section. They said, well, you know.

they had questions about the materials and methods section. They said, well, you know.